Eupraxia Pharmaceuticals (EPRX) vs REGENXBIO (RGNX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Eupraxia Pharmaceuticals (EPRX) has outperformed REGENXBIO (RGNX) over the past year, gaining 29.2% versus a loss of 27.7%. REGENXBIO is the larger company by market cap ($537.7 million vs $499.5 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | EPRX | RGNX |
|---|---|---|
| Share price | $7.56 | $8.15 |
| Market cap | $499.51M | $537.68M |
| 1-day change | -2.83% | +7.24% |
| YTD return | +3.05% | -47.26% |
| 1-year return | +29.24% | -27.74% |
| 5-year return | — | -78.87% |
| EPS (TTM) | $-1.02 | $-3.78 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $9.32 | $16.19 |
| 52-week low | $5.25 | $5.46 |
| Distance from 52-week high | -18.88% | -49.69% |
| Analyst consensus | strong_buy | buy |
| Avg. price target upside | +116.27% | +189.50% |
| Average volume | 567.95K | 1.52M |
| Shares outstanding | 66.07M | 66.01M |
| Employees | 49 | 371 |
| Sector | Health Care | Health Care |
| Industry | Pharmaceuticals and Biotechnology | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- EPRX has outperformed RGNX by 57.0 percentage points over the past year.
About Eupraxia Pharmaceuticals
EPRX stock →Eupraxia Pharmaceuticals Inc., a clinical-stage biotechnology company, focuses on the development of products to address therapeutic areas with unmet medical need. Its proprietary Diffusphere technology optimizes drug delivery for applications with significant unmet medical need.
Health Care · Pharmaceuticals and Biotechnology · 49 employees
About REGENXBIO
RGNX stock →REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 371 employees
EPRX vs RGNX FAQ
Which is bigger, Eupraxia Pharmaceuticals or REGENXBIO?
REGENXBIO (RGNX) is larger, with a market capitalization of $537.68M compared with $499.51M for Eupraxia Pharmaceuticals (EPRX).
Which stock has performed better over the past year, EPRX or RGNX?
EPRX returned +29.24% over the past 12 months, compared with -27.74% for RGNX (price return, excluding dividends). Past performance does not predict future results.
Are Eupraxia Pharmaceuticals and REGENXBIO in the same industry?
Both are in the Health Care sector, but in different industries: Pharmaceuticals and Biotechnology for Eupraxia Pharmaceuticals and Biotechnology: Biological Products (No Diagnostic Substances) for REGENXBIO.